<DOC>
	<DOCNO>NCT00448578</DOCNO>
	<brief_summary>This randomise , double blind , double dummy , multicentre , parallel-group study compare efficacy safety quetiapine lithium use monotherapy treatment mania patient hospitalise acute manic episode . After give informed consent undergo screening procedure , patient randomise quetiapine lithium group Day 1 . The efficacy study treatment symptom mania assess Day 28 . Patients permit use psychoactive antipsychotic medication throughout study period expressly permit protocol . The patient require hospitalised treatment assessment define protocol . He/She could discharge hospital Week 2 ( i.e . On Day 15 ) investigator believe clinical appropriate discharge patient , patient suicidal homicidal , patient could reasonably expect continue study outpatient basis . The patient discharge Day 15 give sufficient study medication period discharge next visit . At centre , individual administer specific psychiatric assessment patient study visit order reduce variability rating scale score . Before initiation study , consistency assessment do among investigator conduct scale assessment centre .</brief_summary>
	<brief_title>Efficacy Safety Seroquel Lithium Monotherapy Acute Mania Treatment Bipolar Disorder Patients</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Written inform consent study participation , sign patient 's legal guardian . Both screen randomization ( Day 1 ) , YMRS total score least 20 . Known intolerance lack response quetiapine lithium , judge investigator . Known suspect hypersensitivity quetiapine lithium .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Acute Mania</keyword>
</DOC>